The Cost-Effectiveness of Sentinel Lymph Node Mapping in High-Risk Endometrial Cancer
2024

Cost-Effectiveness of Sentinel Lymph Node Mapping in High-Risk Endometrial Cancer

publication Evidence: high

Author Information

Author(s): Lara C. Burg, Robin J. Vermeulen, Ruud L. M. Bekkers, Roy F. P. M. Kruitwagen, Petra L. M. Zusterzeel, Gilles Houvenaeghel, André Messori

Primary Institution: Radboud University Medical Center

Hypothesis

Is sentinel lymph node mapping more cost-effective than routine pelvic lymphadenectomy for assessing lymph nodes in high-risk endometrial cancer patients?

Conclusion

Sentinel lymph node mapping is more effective and less expensive than lymphadenectomy for lymph node assessment in high-risk endometrial cancer.

Supporting Evidence

  • Sentinel lymph node mapping was found to be both more effective and less costly than lymphadenectomy.
  • The analysis confirmed that sentinel lymph node mapping is the best option for determining the need for additional treatment in these patients.
  • Quality-adjusted life years (QALYs) were utilized as the measure of effectiveness in the study.
  • SLN mapping leads to less morbidity such as lymphedema compared to lymphadenectomy.
  • The model was validated through various testing methods including expert consultation and sensitivity analyses.

Takeaway

This study shows that using a special mapping technique to check lymph nodes in women with high-risk endometrial cancer is cheaper and works better than the old method.

Methodology

A decision-analytic model was developed to compare sentinel lymph node mapping with pelvic lymphadenectomy based on costs and health outcomes.

Potential Biases

The model relied on expert opinions for some input values, which may introduce bias.

Limitations

Some input values were based on various references, leading to increased heterogeneity, and the model did not account for unknown lymph node statuses in some patients.

Participant Demographics

Patients diagnosed with high-risk endometrial cancer, specifically those with grade 3 endometrioid, serous, or clear cell histology.

Digital Object Identifier (DOI)

10.3390/cancers16244240

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication